Replies to post #191411 on Biotech Values

[DewDiligence]

Re: China’s healthcare insurance

http://in.reuters.com/article/2015/08/02/us-china-healthcare-idINKCN0Q701D20150802

China will expand medical insurance to cover all critical illnesses for all urban and rural residents by the end of the year, the cabinet said on Sunday, the latest step in a plan to fix a healthcare system that has sparked public discontent.

The State Council said 50 percent of the medical costs will be covered by insurance in a bid to "more effectively reduce the burden of medical expenses", in a statement posted on the government's website

…China's healthcare spending is set to hit $1 trillion by 2020, up from $357 billion in 2011, according to McKinsey & Co…

See the chart in #msg-113782571 for related info.

[DewDiligence]

TEVA spends $2.3B to bulk up in Mexico:

http://finance.yahoo.com/news/teva-accelerates-emerging-markets-growth-120000962.html

Teva Pharmaceutical Industries Ltd. today announced that it has entered into definitive agreements under which the Company will acquire Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa), a leading pharmaceutical manufacturing and distribution company in Mexico, along with a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe in a debt-free, cash free set of transactions, for an aggregate of $2.3 billion.

Through this acquisition, Teva will become a leading pharmaceutical company in Mexico, the second largest market in Latin America and one of the top five emerging markets globally.

[DewDiligence]

Chinese drug companies have problems with “suspect” clinical data:

http://health.economictimes.indiatimes.com/news/pharma/china-rejects-11-drug-applications-over-inadequate-trial-data/49763450

China has signalled a tougher stance on drug quality in the country's sprawling pharmaceuticals industry by rejecting applications for 11 medicines with inadequate or suspect clinical data.

The China Food and Drug Administration (CFDA) said in statement posted on its website on Nov. 11 that the move affected eight Chinese companies making generic drugs for heart problems, schizophrenia, pain, infections and other diseases.

A positive for multinational drugmakers who sell products in China.

[DewDiligence]

EM snippet from IMS’ 2020 drug forecast:

http://www.statnews.com/2015/11/18/pharmalot-global-spending-drugs/

By 2020, an estimated 4.5 trillion doses of prescription drugs will be used by patients, up 24% percent [from] this year. In particular, increased usage is expected to jump in China, Brazil, India, and Indonesia, where the middle class is expected to swell and have greater access to health care, according to the IMS Institute for Healthcare Informatics, a unit of IMS Health, the market research firm.

All told, emerging markets will comprise 37% of worldwide drugs sales in 2020, according to the IMS report. More than half of the world’s population will use at least one prescription drug.